IDEXX Laboratories (IDXX) has been performing well as shown by its stock, which surged 75.6% year-to-date. Despite a slide, many investors have been purchasing shares resembling bullish sentiment, including Guggenheim Capital LLC and First Trust Advisors LP. The company posted strong outcomes during Q3 and hiked its guidance. This strong financial performance has led to speculation that IDXX's narrative is shifting. If you invested $1000 in IDEXX 10 years ago, your investment would have proliferated. IDXX has been highlighted as a growth stock due to impressive Q3 results and a raised 2025 guidance. The company's business has managed to stave off economic bears, hitting a record high and was upgraded-to-buy sparking interest among investors. The stock, rallying by 52.9% YTD, has sparked interest in investors such as Baron Focused Growth Fund. IDXX's strong earnings, alongside the 'puppy boom' and pet healthcare demand, have driven the stock up nearly 15%. The price target has been increased by 10.84%. After Q3's earnings beat and lifted full-year outlook, the stock jumped as the firm anticipates more growth in the future. The perception of the company's intrinsic value indicates it's worth US$627, suggesting a slightly undervalued position.
Idexx Laboratories IDXX News Analytics from Wed, 09 Jul 2025 07:00:00 GMT to Sat, 06 Dec 2025 11:51:46 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor 2
